Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 240

Similar articles for PubMed (Select 21155617)

1.

Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.

Stevenson M, Pandor A.

Pharmacoeconomics. 2011 Feb;29(2):133-40. doi: 10.2165/11535770-000000000-00000. Review.

PMID:
21155617
2.

Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.

Stevenson M, Pandor A.

Health Technol Assess. 2009 Oct;13 Suppl 3:37-42. doi: 10.3310/hta13suppl3/06. Review.

3.

Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.

Tosh J, Archer R, Davis S, Stevenson M, Stevens JW.

Pharmacoeconomics. 2013 Aug;31(8):653-61. doi: 10.1007/s40273-013-0052-7. Review.

PMID:
23576019
4.

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N.

Pharmacoeconomics. 2012 Apr;30(4):257-70. doi: 10.2165/11595920-000000000-00000. Review.

PMID:
22283690
5.

Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.

[No authors listed]

Prescrire Int. 2009 Apr;18(100):63-5.

PMID:
19585722
6.

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.

Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M.

Pharmacoeconomics. 2010;28(5):351-62. doi: 10.2165/11532160-000000000-00000. Review.

PMID:
20131924
7.

Febuxostat.

Hair PI, McCormack PL, Keating GM.

Drugs. 2008;68(13):1865-74. Review.

PMID:
18729537
8.

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

Whyte S, Pandor A, Stevenson M.

Pharmacoeconomics. 2012 Dec 1;30(12):1119-32. doi: 10.2165/11597210-000000000-00000. Review.

PMID:
23058097
9.

Cost-effectiveness of febuxostat in chronic gout.

Beard SM, von Scheele BG, Nuki G, Pearson IV.

Eur J Health Econ. 2014 Jun;15(5):453-63. doi: 10.1007/s10198-013-0486-z. Epub 2013 May 30. Erratum in: Eur J Health Econ. 2014 Nov;15(8):897.

PMID:
23719971
10.

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

Bagust A, Greenhalgh J, Boland A, Fleeman N, McLeod C, Dickson R, Dundar Y, Proudlove C, Shaw R.

Pharmacoeconomics. 2010;28(6):439-48. doi: 10.2165/11532220-000000000-00000. Review.

PMID:
20465313
11.

Febuxostat: a new treatment for hyperuricaemia in gout.

Edwards NL.

Rheumatology (Oxford). 2009 May;48 Suppl 2:ii15-ii19. doi: 10.1093/rheumatology/kep088. Review.

12.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
13.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.

N Engl J Med. 2005 Dec 8;353(23):2450-61.

14.

Febuxostat for treating chronic gout.

Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008653. doi: 10.1002/14651858.CD008653.pub2. Review.

15.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

16.

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.

Rafia R, Simpson E, Stevenson M, Papaioannou D.

Pharmacoeconomics. 2013 Jun;31(6):471-8. doi: 10.1007/s40273-013-0044-7. Review.

PMID:
23568332
17.

Febuxostat for prevention of gout attacks.

Pohar S, Murphy G.

Issues Emerg Health Technol. 2006 Aug;(87):1-4.

PMID:
16958189
18.

Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.

McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper C, Woolacott N, Palmer S.

Pharmacoeconomics. 2012 Jan;30(1):35-46. doi: 10.2165/11594280-000000000-00000. Review.

PMID:
22136303
19.

An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.

Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.

J Clin Rheumatol. 2011 Jun;17(4 Suppl 2):S13-8. doi: 10.1097/RHU.0b013e31821d36cc.

PMID:
21654265
20.

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.

J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13.

PMID:
19286847
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk